📣 VC round data is live. Check it out!
- Public Comps
- Biomea Fusion
Biomea Fusion Valuation Multiples
Discover revenue and EBITDA valuation multiples for Biomea Fusion and similar public comparables like Adocia, Actinogen Medical, Inovio Pharmaceuticals, Faron Pharmaceuticals and more.
Biomea Fusion Overview
About Biomea Fusion
Biomea Fusion Inc is a clinical-stage diabetes and obesity medicines company focused on the discovery and development of oral covalent small-molecule drugs to treat patients with metabolic diseases. The company uses its proprietary FUSION System discovery platform to develop a pipeline of novel small-molecule product candidates. Its principal clinical program’s drug candidate, icovamenib, is being developed as an orally bioavailable, selective covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib’s potential in type 1 and type 2 diabetes, as well as its impact in obesity. The company is also developing BMF-650, an investigational, oral small-molecule GLP-1 RA, which has the potential to be a therapeutic option for diabetes and obesity.
Founded
2017
HQ

Employees
106
Website
Financials (LTM)
EV
$70M
Valuation Multiples
Start free trialBiomea Fusion Financials
Biomea Fusion reported last 12-month revenue of — and negative EBITDA of ($78M).
In the same LTM period, Biomea Fusion generated — in gross profit, ($78M) in EBITDA losses, and had net loss of ($65M).
Revenue (LTM)
Biomea Fusion P&L
In the most recent fiscal year, Biomea Fusion reported revenue of — and EBITDA of ($80M).
Biomea Fusion is unprofitable as of last fiscal year, with EBITDA margin of — and net margin of —.
Financial data powered by Morningstar, Inc.
Biomea Fusion Stock Performance
Biomea Fusion has current market cap of $114M, and enterprise value of $70M.
Market Cap Evolution
Biomea Fusion's stock price is $1.58.
Biomea Fusion share price increased by 15.8% in the last 30 days, and by 9.4% in the last year.
Biomea Fusion has an EPS (earnings per share) of $-0.85.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $70M | $114M | 1.0% | 15.8% | 17.6% | 9.4% | $-0.85 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialBiomea Fusion Valuation Multiples
Biomea Fusion trades at (0.9x) EV/EBITDA.
EV / Revenue (LTM)
Biomea Fusion Financial Valuation Multiples
As of May 13, 2026, Biomea Fusion has market cap of $114M and EV of $70M.
Biomea Fusion has a P/E ratio of (1.8x).
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Biomea Fusion Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


Biomea Fusion Margins & Growth Rates
Biomea Fusion decreased EBITDA by 12% in the last fiscal year.
Biomea Fusion Growth Rates
Data powered by FactSet, Inc. and Morningstar, Inc.
Biomea Fusion Operational KPIs
Biomea Fusion's revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $0.8M for the same period.
Data powered by FactSet, Inc. and Morningstar, Inc.
Biomea Fusion Competitors
Biomea Fusion competitors include Adocia, Actinogen Medical, Inovio Pharmaceuticals, Faron Pharmaceuticals, PepGen, Nykode Therapeutics, Cardiff Oncology, Kalaris Therapeutics, Fractyl Health and Rani Therapeutics.
Most Biomea Fusion public comparables operate across Biopharmaceuticals, BioTech and DeepTech.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| 23.0x | 14.5x | (5.7x) | (6.2x) | |||
| — | 31.3x | — | (8.4x) | |||
| 1008.5x | 16.4x | (0.8x) | — | |||
| 336.4x | 529.2x | (5.6x) | (5.4x) | |||
| — | — | 0.2x | — | |||
| — | — | (3.5x) | (1.7x) | |||
| 92.2x | 109.3x | (1.1x) | — | |||
| — | — | 0.2x | 0.1x | |||
This data is available for Pro users. Sign up to see all Biomea Fusion competitors and their valuation data. Start Free Trial | ||||||
Biomea Fusion Funding History
Before going public, Biomea Fusion raised $56M in total equity funding, across 1 round.
Biomea Fusion Funding Rounds
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Biomea Fusion
| When was Biomea Fusion founded? | Biomea Fusion was founded in 2017. |
| Where is Biomea Fusion headquartered? | Biomea Fusion is headquartered in United States. |
| How many employees does Biomea Fusion have? | As of today, Biomea Fusion has over 106 employees. |
| Who is the CEO of Biomea Fusion? | Biomea Fusion's CEO is Michael J. M. Hitchcock. |
| Is Biomea Fusion publicly listed? | Yes, Biomea Fusion is a public company listed on Nasdaq. |
| What is the stock symbol of Biomea Fusion? | Biomea Fusion trades under BMEA ticker. |
| When did Biomea Fusion go public? | Biomea Fusion went public in 2021. |
| Who are competitors of Biomea Fusion? | Biomea Fusion main competitors include Adocia, Actinogen Medical, Inovio Pharmaceuticals, Faron Pharmaceuticals, PepGen, Nykode Therapeutics, Cardiff Oncology, Kalaris Therapeutics, Fractyl Health, Rani Therapeutics. |
| What is the current market cap of Biomea Fusion? | Biomea Fusion's current market cap is $114M. |
| Is Biomea Fusion profitable? | No, Biomea Fusion is not profitable. |
| What is the current EBITDA of Biomea Fusion? | Biomea Fusion has negative EBITDA and is not profitable. |
| What is the current EV/EBITDA multiple of Biomea Fusion? | Current EBITDA multiple of Biomea Fusion is (0.9x). |
| What is the current FCF of Biomea Fusion? | Biomea Fusion's last 12 months FCF is ($66M). |
| What is the current EV/FCF multiple of Biomea Fusion? | Current FCF multiple of Biomea Fusion is (1.1x). |
| How many companies Biomea Fusion has acquired to date? | Biomea Fusion hasn't acquired any companies yet (or none have been disclosed publicly). |
| In how many companies Biomea Fusion has invested to date? | Biomea Fusion hasn't invested in any companies yet (or none have been disclosed publicly). |
See public comps similar to Biomea Fusion
Lists including Biomea Fusion
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.